2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM: Abstract Number: 2615

Non-Pharmacological Treatment on Fatigue, Depression, Disease Activity, and Quality of Life of Systemic Lupus Erythematosus: A Systematic Review

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

9:00AM-11:00AM: Abstract Number: 2601

Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation in SLE Patient PBMC and in Trex1-/- Mouse Spleen and Heart

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

9:00AM-11:00AM: Abstract Number: 2175

Novel Assessment of Interstitial Lung Disease Using the “Computer-Aided Lung Informatics for Pathology Evaluation and Rating” Software System in Idiopathic Inflammatory Myopathies

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 2362

Novel Biomarkers for the Prediction of Subclinical Coronary Artery Atherosclerosis in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2337

Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) and Myositis Autoantibody Groups

Pediatric Rheumatology – Pathogenesis and Genetics Poster

9:00AM-11:00AM: Abstract Number: 2508

Obese Axial Spondyloarthropathy Patients Have Worse Disease Outcomes

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

9:00AM-11:00AM: Abstract Number: 2372

Obesity and the Impact on Treat to Target Goals and Functional Ability in RA. Results from Two Multi-Centre UK Inception Cohorts

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2374

Obesity Impacts ESR and Not Other Measures of Rheumatoid Arthritis Disease Activity

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2263

Obesity Independently Associates with Worse Patient Reported Outcomes in Women with Systemic Lupus Erythematosus

Patient Outcomes, Preferences, and Attitudes Poster III

9:00AM-11:00AM: Abstract Number: 2417

Occult Coronary Plaque Presence and Burden Predict Cardiovascular Events in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 1968

Occurrence of Rheumatic Diseases in a National Cohort of Hospitalizations for Progressive Multifocal Leukoencephalopathy

Epidemiology and Public Health Poster III: Rheumatic Disease Risk and Outcomes

9:00AM-11:00AM: Abstract Number: 2409

Older Age and Male Gender Are Independent Predictors of Quantiferon Positivity Among Adult Rheumatic Patients in a Tertiary Care Center from a BCG Vaccinated Country: Hur-BIO Single Center Real Life Results

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2055

Omeract Ultrasonographic Criteria for the Diagnosis of Calcium Pyrophosphate Deposition Disease at the Metacarpal-Phalangeal, Wrist, Acromion-Clavicular and Hip Joints: An Inter-Observer and Intra-Observer Reliability Study

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2739

Onco-Hematological Malignancies in Systemic Necrotizing Vasculitides: Pooled Analysis of Five Prospective, Randomized, Controlled Trials

Vasculitis Poster III: Other Vasculitis Syndromes

9:00AM-11:00AM: Abstract Number: 2031

Online Viewing of Labs in RA Patients Is Not Associated with Clinically Significant Change in ESR over 18 Months Compared to Non-Viewers

Measures and Measurement of Healthcare Quality Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].